Nifedipine Treatment on Uterine Contractility in IVF
Status:
Unknown status
Trial end date:
2018-06-01
Target enrollment:
Participant gender:
Summary
The main factors associated with pregnancy rate in In Vitro Fertilization (IVF) treatment are
embryo quality and the uterine ability to accept the embryo for implantation. This ability is
influenced by uterine contractions (UC), which change in pattern and direction during the
menstrual cycle. An abnormal uterine contraction pattern can displace the embryo from the
proper position in the uterine cavity towards the cervix or the fallopian tubes and as a
result may decrease pregnancy rates and increase the risk of ectopic pregnancy. Indeed,
previous studies demonstrated a negative correlation between uterine contraction rate and
implantation/pregnancy rates. Suppression of uterine contractions during embryo transfer can
be achieved by a large array of drugs, such as cyclo-oxygenase inhibitors, β2-adrenoreceptor
agonists, calcium-channel blockers, phosphodiesterase inhibitors and oxytocin antagonists.
The objective of this study is to evaluate the efficacy of Nifedipine administration in
reducing uterine contractility during IVF-frozen embryo transfer (FET) treatment.